Orum Therapeutics begins first patient dosing in Phase 1 trial of blood cancer treatment 'ORM-1153'
Predicted impact: Low· Actual: −11.2% vs sector, volume 0.3× normal (5 trading days)
Phase 1 first patient dosing; early-stage clinical step with no near-term revenue size.